{"AmendmentNumber":"495","ParentBillNumber":"H5562","Bill":null,"Sponsor":{"Id":"MCD1","Name":"Marjorie C. Decker","Type":1,"Details":"https://malegislature.gov/api/GeneralCourts/194/LegislativeMembers/MCD1","ResponseDate":"2026-07-06T15:08:40.027"},"Category":null,"Action":"Consolidated","RollCall":[],"Title":"Pilot for the use of psychedelics in licensed treatment facilities","Branch":"House","RedraftNumber":null,"IsFurther":false,"GeneralCourtNumber":194,"Text":"Ms. Decker of Cambridge moves to amend the bill by adding the following section:\r\nSECTION XX: Notwithstanding any general or special law to the contrary, the department of public health shall establish a pilot program to allow for the monitored mental health care of clinically appropriate patients using naturally occurring psychedelic materials as defined by the department of public health for on-site administration by a multi-disciplinary care team in a supervised licensed mental health clinic setting. The department shall issue pilot permits to no more than three licensed mental health clinic facilities to participate in the pilot program for the purposes of establishing the best and safest clinical practices for psychedelic mental health treatment programs in the commonwealth and for the purposes of collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy. Authorization shall be given to clinics licensed in mental health services as defined by the department of public health. Eligible pilot program organizations must exclusively focus operations and treatment on mental health and cannot be subsidiaries, affiliates or members of cannabis industry organizations, psychedelic molecule development companies or pharmaceutical companies.\r\nThe department shall promulgate the rules and regulations necessary for the operation of a supervised psychedelic pilot in a clinical setting, including but not limited to, establishing a process to apply for participation in the pilot. The regulations must include but not be limited to: the definitions and standards for clinic participation; the process of initial patient assessment and ongoing monitoring; the composition of the clinical staff and the role of a licensed physician to oversee the program; the process of ensuring coordination and medical management of psychiatric medications with prescribers outside of the participating outpatient clinical pilot; and, the process of storage, dispensing and administration of psychedelics within the participating pilot. The department shall establish by regulation all standards and requirements governing the production and cultivation of naturally occurring psychedelic materials necessary for the pilot program, including but not limited to producer licensing and operations.\r\nThe provisions of chapter 94C, section 2 of the General Laws that include psilocybin and psilocin as Schedule I controlled substances shall not apply to the medical use of psilocybin and psilocin as provided under the pilot program and regulations promulgated hereunder. A licensed mental health clinic facility, designated participant, licensed clinical staff member, or patient acting in compliance with the pilot program and regulations promulgated hereunder shall not be subject to arrest, prosecution, or civil or professional penalty under state law for activities expressly authorized under the pilot program. A licensed health care practitioner shall not be subject to professional discipline or loss of licensure solely for issuing a written certification under the pilot program, recommending participation in the program to a patient, or providing medical services authorized under the program.\r\nThe department shall coordinate with research institutions, as it deems appropriate, to facilitate, expand and expedite federally-authorized research on psychedelic-assisted therapies, including but not limited to psilocybin, ibogaine, 5-methoxy-n,n-dimethyltryptamine, and 3,4-methylenedioxymethamphetamine, in the commonwealth, including efforts to pursue federal approvals and available state and federal funding in compliance with applicable federal regulations.\r\nAll pilot program participant organizations must track patient care outcomes data related to the identification, diagnosis and psychedelic treatment of depression, anxiety, post-traumatic stress disorder and substance use disorder. These data sets must be shared with the department to assist in the refinement of best clinical protocols and final regulatory frameworks for the safe use of psychedelic material in Massachusetts.\r\nThere is hereby established a \"medical psychedelics fund\" as a nonreverting fund. The fund shall consist of appropriations, gifts, grants, and donations and shall be administered by the department for the purposes of this program.\r\n"}